

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Joseph M. Penninger  
Michael A. Crackower

Serial No.: 10/518,599

Filed: May 31, 2005

For: ACE2 ACTIVATION FOR TREATMENT  
OF HEART, LUNG AND KIDNEY  
DISEASE AND HYPERTENSION

Group Art Unit: 1632

Examiner: Anoop Kumar Singh

Atty. Dkt. No.: SONN:064US

**CERTIFICATE OF ELECTRONIC SUBMISSION**

DATE OF SUBMISSION: August 8, 2006

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If the fee has been inadvertently omitted, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/SONN:064US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Travis Wohlers  
Reg. No. 57,423  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: August 8, 2006

|   |   |  |                          |
|---|---|--|--------------------------|
| Form PTO-1449 (modified)  |   | Atty. Docket No.<br>SONN:064US                           | Serial No.<br>10/518,599 |
| List of Patents and Publications for Applicant's<br><br>INFORMATION DISCLOSURE STATEMENT<br><br>(Use several sheets if necessary) |   | Applicant<br>Joseph M. Penninger<br>Michael A. Crackower |                          |
|   |   | Filing Date:<br>May 31, 2005                             | Group:<br>1632           |
| U.S. Patent Documents<br><i>See Page 1</i>  | Foreign Patent Documents<br><i>See Page 1</i> | Other Art<br><i>See Page 1</i>                           |                          |

### U.S. Patent Documents

| Exam.<br>Init. | Ref.<br>Des. | Document<br>Number | Date | Name | Class | Sub<br>Class | Filing Date<br>of App. |
|----------------|--------------|--------------------|------|------|-------|--------------|------------------------|
|                |              |                    |      |      |       |              |                        |

### Foreign Patent Documents

| Exam.<br>Init. | Ref.<br>Des. | Document<br>Number | Date | Country | Language |
|----------------|--------------|--------------------|------|---------|----------|
|                |              |                    |      |         |          |

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam.<br>Init. | Ref.<br>Des. | Citation  |
|----------------|--------------|---|
|                | C60          | BLASTP 2.2.14 search for peptide DRVYIHPF Angiotensin II in all GenBank databases, May 7, 2006.   |
|                | C61          | Imai <i>et al.</i> , "Angiotensin-converting enzyme 2 protects from severe acute lung failure," <i>Nature</i> , 436:112-116, 2005.  |
|                | C62          | Kuba <i>et al.</i> , "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury," <i>Nature Medicine</i> , 11(8):875-879, 2005.                |
|                | C63          | Macours <i>et al.</i> , "Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes," <i>International Review of Cytology</i> , 239:47-97. |

25683602.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.